(HealthDay)—Sotrovimab reduces the risk for disease progression in high-risk patients with mild-to-moderate COVID-19, according to a study published online
(HealthDay)—Clinically active inflammatory bowel disease (IBD) is associated with adverse COVID-19 outcomes, especially in younger and middle-aged adults, according
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok